PlainRecalls
FDA Drug Moderate Class II Terminated

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Reported: December 23, 2020 Initiated: December 14, 2020 #D-0165-2021

Product Description

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Reason for Recall

cGMP deviations: Vials may not be sealed correctly affecting sterility.

Details

Recalling Firm
CIPLA
Units Affected
2151 vials
Distribution
USA Nationwide
Location
Warren, NJ

Frequently Asked Questions

What product was recalled?
Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40. Recalled by CIPLA. Units affected: 2151 vials.
Why was this product recalled?
cGMP deviations: Vials may not be sealed correctly affecting sterility.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 23, 2020. Severity: Moderate. Recall number: D-0165-2021.